(RTTNews) - Bayer (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE) announced that the European Commission has granted approval in the European Union for Kerendia or finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist for the treatment of adults with heart failure with left ventricular ejection fraction =40%. In the EU, Kerendia is now indicated for the treatment of symptomatic chronic heart failure with LVEF =40% in adults, expanding its use beyond the existing indication in patients with chronic kidney disease associated with type 2 diabetes.
The approval by the European Commission is based on the positive results from the pivotal Phase III FINEARTS-HF study.
At last close, Bayer shares were trading at 38.26 euros.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
